Henriette Mersebach

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Peter Rossing, Florian M.M. Baeres, George L. Bakris et al. · Nephrology Dialysis Transplantation · 2023 · 237 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects

Moshe Hod, Peter Damm, Risto Kaaja et al. · American Journal of Obstetrics and Gynecology · 2007 · 174 citations

Medicine, Endocrinology, Obstetrics +12

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

Stephen Gough, Anuj Bhargava, Rajeev Jain et al. · Diabetes Care · 2013 · 151 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

Gregory Fulcher, Jens Sandahl Christiansen, Ganapathi Bantwal et al. · Diabetes Care · 2014 · 111 citations

Medicine, Endocrinology, Pharmacotherapy +17

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes

Tim Heise, Cees J. Tack, Robert Cuddihy et al. · Diabetes Care · 2011 · 96 citations · Full text

Medicine, Endocrinology, Pharmacology +17